Ironwood Pharmaceuticals Inc - Class A (IRWD) Company Profile & Statistics

Ironwood Pharmaceuticals Inc - Class A
IRWD
(Nasdaq - US)
N/A
8.10
+0.00 (-0.06%)
in:usd•As of: Apr 25, 2024 15:59 UTC -4
Open
7.96
High
8.14
Low
7.96

About Ironwood Pharmaceuticals Inc - Class A

CEO

Thomas McCourt

Headquarters

100 summer street, suite 2300

boston, ma 02110, united states

Auditor

Ernst & Young LLP

Employees

267

Share Holders

Website

www.ironwoodpharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

Ironwood Pharmaceuticals Inc - Class A Statistics

Valuation Measures

Market Capitalization ²	1.30B
Enterprise Value	1.91B
Enterprise Value/EBITDA (ttm)	-2.02
Price to Earnings Ratio (ttm)	12.22
Price to Book (mrq)	N/A
Price to Sales (ttm)	2.94
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	32.66%
Profit Margin (ttm)	-233.17%
Return on Equity (ttm)	-185.45%
Return on Invested Capital (ttm)	-421.33%
Return on Assets (ttm)	21.00%

Income Statement

Revenue (ttm)	442.74M
Revenue Per Share (ttm)	2.83
Gross Profit (ttm)	442.74M
EBITDA (ttm)³	-943.85M
Net Income Avi to Common (ttm)	-1.00B
Diluted EPS (ttm)	-6.51

Share Statistics

Beta (5Y Monthly)	0.55
52-Week Change	-23.12%
S&P500 52-Week Change	23.88%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	156.53M
Dividend Yield	0.00%
Float ⁴	136.02M
% Held by Insiders	13.10%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	92.15M
Total Cash Per Share (mrq)	0.59
Total Debt (mrq)	697.87M
Total Debt/Equity (mrq)	-201.52%
Current Ratio (mrq)	0.84%
Quick Ratio (mrq)	0.84%
Book Value Per Share (mrq)	-2.21

Cash Flow

Operating Cash Flow Per Share (ytd)	1.18
Free Cash Flow (ytd)	183.15M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Ironwood Pharmaceuticals Inc - Class A

Trade With A Regulated Broker